==== Front Oncol RepOncol. RepOncology Reports1021-335X1791-2431D.A. Spandidos 2991653410.3892/or.2018.6506or-40-02-0647ArticlesAberrantly expressed genes and miRNAs in human hypopharyngeal squamous cell carcinoma based on RNA-sequencing analysis Li Hu 1Wang Fuling 2Fei Yonghua 1Lei Yanhua 1Lu Fengxiang 1Guo Ping 1Li Wei 1Xun Xuehong 11 Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, Jining, Shandong 272000, P.R. China2 Department of Obstetrics, The First Maternity and Child Health Hospital of Jining, Jining, Shandong 272000, P.R. ChinaCorrespondence to: Dr Ping Guo, Department of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Jining, 6 Jiankang Road, Rencheng, Jining, Shandong 272000, P.R. China, E-mail: guo_ping720608@163.com8 2018 19 6 2018 19 6 2018 40 2 647 658 21 12 2017 04 6 2018 Copyright: © Li et al.2018This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.The aim of the present study was to investigate the key genes, miRNAs and pathways in hypopharyngeal squamous cell carcinoma (HPSCC) and to elucidate the mechanisms underlying HPSCC development. The gene and microRNA (miRNA) expression profiles of HPSCC tissues and adjacent normal tissues from three subjects were obtained. Differentially expressed genes (DEGs) and differentially expressed miRNAs were identified in HPSCC. Functional annotation and protein-protein interaction (PPI) network were conducted to elucidate the biological functions of DEGs. A total of 160 DEGs (16 upregulated and 144 downregulated genes) and 79 differentially expressed miRNAs (48 upregulated and 31 downregulated miRNAs) were identified in HPSCC. The deregulated genes were significantly involved in spliceosome, cell cycle and RNA degradation. In the PPI network, S-phase kinase associated protein 1 (SKP1), non-POU domain containing octamer binding (NONO) and zinc activated ion channel (ZACN) were identified as hub proteins. On the whole, the present study may help to gain a comprehensive understanding of tumorigenesis in HPSCC and provide valuable information for early diagnosis and drug design of HPSCC in future research. hypopharyngeal squamous cell carcinomaRNA-sequencingdifferentially expressed genesprotein-protein interaction networkexpression profiling ==== Body Introduction Hypopharyngeal squamous cell carcinoma (HPSCC) is a common type of head and neck cancer that is associated with a high invasiveness and a poor prognosis. Recently, surgical resection along with chemoradiation therapy have been indicated as a good modality for HPSCC treatment; however, the majority of patients with HPSCC have an unfavorable prognosis due to diagnosis at an advanced stage with the presence of distant metastasis and therefore, the opportunity for radical treatment is lost. It has been reported that the overall survival rate of patients with HPSCC is only 15–45% (1,2). The etiological factors of HPSCC are unclear. A series of recent studies have described that smoking (active and passive), alcohol consumption and exposure to the human papilloma virus may be risk factors for the development of HPSCC (3–5). The pathophysiological mechanisms of HPSCC are not yet well understood. Previous studies have demonstrated that ectopically expressed genes, microRNAs (miRNAs or miRs) and long non-coding RNAs were involved in the initiation, development and prognosis of HPSCC. Tumor necrosis factor receptor 1 (TNFR1) is a membranous receptor that anchors on the surface of the cell membrane, which belongs to the TNF receptor superfamily (6,7). The upregulation of TNFR1 has been shown to be associated with clinical staging, T stage, cervical lymph node metastasis and histological grade in HPSCC (8). The immunoglobulin heavy chain binding protein (BiP)/glucose-regulated protein 78 (GRP78) plays an important role in the endoplasmic reticulum stress and is known to be highly expressed in various human neoplasms. A decreased expression of GRP78/BiP has been reported to predict a poor overall survival and progression-free survival of patients with advanced HPSCC (9). The downregulation of miR-140-5p has also been shown to be associated with tumor stage and lymph node metastasis, and the restoration of miR-140-5p inhibits cell migration and invasion in HPSCC by targeting ADAM metallopeptidase (ADAM10), which is involved in the Notch1 signaling pathway (10). The expression of AB209630, a long non-coding RNA, has been shown to be markedly lower in HPSCC cell lines and tumor tissues compared with the normal cells and tissues, and functions as a tumor suppressor in HPSCC. A high expression of AB209630 significantly has been shown to inhibit the growth, metastasis and invasion of HSPCC in vitro, and a decreased expression of AB209630 predicts a poorer prognosis (11). In addition, abnormal methylation is associated with tumorigenesis in HSPCC. The hypermethylation of G protein-coupled receptor kinase 6 (GRK6) has been observed in HPSCC tissues compared to the matched adjacent normal tissues. GRK6 is also associated with tumor invasion and TNM stage in HPSCC (12). HPSCC is a common malignancy with a poor prognosis. To the best of our knowledge, the expression profiling of mRNAs and miRNAs via RNA-sequencing has not yet been documented in HPSCC. In the present study, we used high-throughput RNA-sequencing to examine gene and miRNA expression and to investigate the functional significance of aberrantly expressed genes and miRNAs in HSPCC, with the aim of providing the groundwork for the elucidation of HPSCC tumorigenesis and potential biomarkers for the early diagnosis of HPSCC. Materials and methods Patients and samples A total of 3 patients diagnosed with HPSCC were enrolled in this study from the First People's Hospital of Jining from August, 2015 to January, 2016. The mean age of the 3 patients with HPSCC was 60.7 years (range, 56–64 years). All 3 patients with HPSCC patients with squamous cell carcinoma were male. All patients had lymph node metastasis tumor loci. Primary HPSCC tissues and adjacent normal tissues of patients were obtained through surgical resection. The TNM stage and tumor grade of the patients are presented in Table I. The study was approved by the Ethics Committee of the First People's Hospital of Jining, and informed written consent was obtained from all patients. Primary tumors and adjacent normal tissues of patients with HPSCC were obtained based on the Declaration of Helsinki. Isolation of RNA A total of 6 specimens from the 3 patients were used for RNA isolation using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. RNA quality and quantity were assessed using the NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific) and Agilent 2100 bioanalyzer (Agilent Technologies GmbH, Waldron, Germany). The average RNA quantity for the specimens was 73.42 µg (0.84–174.98 µg) with RNA integrity number (RIN) values between 1.0 and 7.6. Library preparation and RNA sequencing The Illumina TruSeq RNA Sample Prep kit (Illumina, Inc., San Diego, CA, USA) was used for the library preparation according to the manual. PolyT oligo-conjugated magnetic beads were used to enrich the RNA with polyA+ tail, followed by mRNA fragmentation, first strand cDNA synthesis, second strand cDNA synthesis and end repair. Subsequenlty, the product was ligated to Illumina TruSeq adaptors. Following PCR amplification, enriched cDNA libraries were sequenced using the Illumina HiSeq 2500 sequencing platform (Illumina). Data preprocessing The raw data from high-throughput RNA-sequencing was translated into raw FASTQ sequence data by base calling. Raw RNA-sequencing data were filtered and trimmed using FASTx-Tool SeqPrep (https://github.com/jstjohn/SeqPrep) and Sickle (https://github.com/najoshi/sickle). Clean and trimmed FASTQ reads were aligned to the human hg19 genome by using TopHat (version 1.3.1; Center for Computational Biology, Johns Hopkins University, Baltimore, MD, USA) (13). The aligned read files were then processed using Cufflinks version 1.2.1 software package (Trapnell Lab, Seattle, WA, USA) which assessed the abundance of genes (14). Fragments per kilobase of transcript per million mapped reads (FPKM) was used to determine the transcription abundance of each gene. Differentially expressed genes (DEGs) and miRNAs The DEGs between HPSCC tumor and adjacent normal tissues were carried out using paired t-tests and limma package in R (15). The false discovery rate (FDR) was performed; multiple testing corrections of raw P-values were performed using the Benjamini and Hochberg method (16,17). The genes with an FDR <0.05 and abs (log2 fold change) >1 were screened as DEGs. A two-way hierarchical clustering analysis was conducted to assess the similarity of gene expression patterns between samples, and the results were displayed in a heatmap using the ‘pheatmap’ package (18). In addition, DEGseq (http://bioconductor.org/packages/DEGseq/) was applied to quantify the expression of miRNAs. miRNAs with P-value <0.001 and abs (log2FC) >2 were screened as differentially expressed miRNAs. Analysis of the miRNA target genes Identifying the target genes of miRNAs is a key step towards studying the function of miRNAs in specific tissues and cells. In the present study, 6 miRNA-target prediction tools (DIANAmT, miRanda, miRDB, miRWalk, PICTAR5 and TargetScan) were applied to predict the target genes of differentially expressed miRNAs. The miRNA-targets that were predicted by >4 algorithms or verified by experiment in the miRWalk database were identified. All miRNA-target pairs were obtained, which were not only predicted by algorithms (or verified by experiment), but also negatively associated in the expression level. The miRNA-target regulatory network was then constructed, which was visualized using Cytoscape (19). Functional annotation of DEGs The Gene Ontology (GO) function was used to elucidate the biological function of DEGs in biological process, molecular function and cellular component using the GeneCodis 3 online software (http://genecodis.cnb.csic.es/analysis) (20). P<0.01 was set as the cut-off for selecting significantly enriched functional GO terms. KOBAS version 2.0 software (http://kobas.cbi.pku.edu.cn) was used to enrich the signaling pathways of DEGs (21). P<0.05 was set as the threshold for determining significantly enriched pathways. Protein-protein interaction network (PPI) In order to elucidate the protein interactions between upregulated and downregulated DEGs in HPSCC, the BioGRID database was used to screen pairs of interacting proteins (22). The PPI network was visualized using Cytoscape (http://cytoscape.org/) (23). In the network, nodes represent proteins and edges represent interaction between two proteins. Validation of the expression of selected DEGs in The Cancer Genome Atlas (TCGA) TCGA dataset was used to validate the expression of selected DEGs in HPSCC patients with a large sample size by using the online software SurvExpress (http://bioinformatica.mty. itesm.mx:8080/Biomatec/SurvivaX.jsp). Results RNA sequencing of HPSCC specimens Total RNA was extracted from HPSCC tissues and adjacent normal controls from 3 patients. A total of 5 out of 6 samples, including 1C, 1N, 3C, 3N and 2C passed the assessment for RNA quality and quantity. Sample 2N did not pass the assessment, as the RIN value was not applicable (Table II). A total of 5 samples were used for library construction and RNA-sequencing. For each sample, RNA-sequencing reads were generated and yielded 34–44 million sequencing reads per sample (Table III). All sequencing reads were aligned to the human hg19 genome by using TopHat and FPKM and the relative expression of genes was determined using the Cufflinks tool. DEGs and differentially expressed miRNAs between primary HPSCC and adjacent normal controls A total of 160 DEGs, including 16 upregulated and 144 downregulated genes, were identified in the HPSCC tumors compared to the adjacent normal controls using the screening criteria FDR<0.05 and abs (log2FC) >1 (data not shown). In addition, a total of 79 differentially expressed miRNAs (48 upregulated and 31 downregulated miRNAs) were identified in the HPSCC tumors compared to adjacent normal controls using the screening criteria P<0.001 and abs (log2FC) >2 (data not shown). As shown in Table IV, zinc activated ion channel (ZACN), chorionic gonadotropin β subunit 3 (CGB3) and zinc finger protein 385C (ZNF385C) were the top 3 upregulated genes. Ribosomal protein L26 (RPL26), ribosomal protein S6 (RPS6) and S-phase kinase associated protein 1 (SKP1) were the top 3 downregulated genes in HPSCC. The expression pattern of the top 20 upregulated and downregulated DEGs was examined by two-way hierarchical clustering analysis (Fig. 1). Compared to the normal control, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was a significantly downregulated long non-coding RNA in HPSCC based on our RNA-sequencing data (FDR=0.014705). The top 20 differentially expressed miRNAs are shown in Table V. As shown in Table V, hsa-let-7i-5p, hsa-miR-136-5p and hsa-miR-143-5p were the top 3 upregulated miRNAs in HPSCC, and hsa-miR-15a-5p, hsa-miR-2278 and hsa-miR-125a-5p were the top 3 downregulated miRNAs in HPSCC. miRNA target gene interactions Following target correlation analysis, a total of 339 miRNA-target pairs were obtained in HPSCC. A total of 228 upregulated miRNA-target pairs and 9 downregulated miRNA-target pairs were predicted using 6 prediction tools. A total of 101 upregulated miRNAs-target pairs and 1 downregulated miRNAs-target pair were validated in the miRWalk dataset. The top 10 miRNAs that targeted the majority of genes are listed in Table VI. The miRNA-target network between DEGs and differentially expressed miRNAs is presented in Fig. 2. Functional annotation of DEGs GO annotation of the 160 identified DEGs in HPSCC was performed to elucidate the biological roles of DEGs using the GeneCodis 3 online software. P<0.05 was used to determine significantly enriched GO terms. The most enriched ‘molecular functions’ of the DEGs were carbon-sulfur lyase activity (GO, 0016846), phosphotransferase activity, for other substituted phosphate groups (GO, 0016780) and CDP-alcohol phosphatidyltransferase activity (GO, 0017169). The most enriched ‘cellular components’ were intracellular organelle part (GO, 0044446), organelle part (GO, 0044422) and cytoplasm (GO, 0005737). The most enriched ‘biological processes’ were mRNA metabolic process (GO, 0016071), RNA processing (GO, 0006396) and RNA splicing (GO, 0008380) (Figs. 3–5). KEGG pathway enrichment We performed KEGG pathway enrichment analysis for DEGs using KOBAS version 2.0. P<0.05 was used as the criteria for pathway enrichment. The most enriched pathways were spliceosome (hsa03040), cell cycle (hsa04110) and RNA degradation (hsa03018) (Fig. 6). PPI network of DEGs in primary HPSCC compared to adjacent normal controls PPI networks of the top 20 upregulated and downregulated DEGs in HPSCC compared to adjacent normal controls were determined using Cytoscape, which consisted of 673 nodes and 812 edges (data not shown). The proteins that had high connectivity with other proteins were hub proteins. In the PPI network, SKP1, NONO and ZACN were the hub proteins, which interacted with 166, 101 and 70 proteins, respectively (Fig. 7). Expression validation of selected DEGs in TCGA A total of 5 DEGs [SKP1, ZACN, NONO, cold shock domain containing E1 (CSDE1), chorionic gonadotropin β subunit 3 (CGB3) and MALAT1] were selected to perform the tumor risk evaluation in HPSCC by using the head and neck squamous cell carcinoma datasets (283 samples) in TCGA. CGB3, SKP1 and ZACN were upregulated while MALAT1, NONO and CSDE1 were downregulated in the HPSCC high-risk group (Fig. 8). Additionally, we also performed validation of SKP1, NONO and MALAT1 using the HPSCC dataset in TCGA. The result showed that the expression of SKP1, NONO and MALAT1 was decreased in HPSCC tissues compared to the normal control, which was consistent with the RNA-sequencing analysis (Fig. 9). Discussion At present, there is a lack of early detection biomarkers in clinical practice for HPSCC. To the best our knowledge, this is the first study to report the expression pattern of mRNAs and miRNAs in HPSCC via high-throughput RNA sequencing. SKP1 was significantly downregulated in HPSCC compared to adjacent normal controls (Table IV). SKP1 had the highest connectivity with 193 proteins (Fig. 7). According to KEGG signaling pathway enrichment, SKP1 was significantly enriched in cell cycle and circadian rhythm. In homo sapiens, SKP1 encodes S-phase kinase-associated protein 1, which is a scaffold protein of the ubiquitin E3 ligase Skp1/Cullin1/Rbx1/F-box protein complex (SCF complex). The SCF complex catalyzes the ubiquitination of proteins, which are involved in cell-cycle progression, signal transduction and transcription (24). SKP1 was overexpressed in 56.3% of the non-small cell lung cancer (NSCLC) specimens and elevated SKP1 was associated with a poor prognosis (25). The other component of the SCF complex, cullin, is highly expressed in NSCLC tissues and significantly associated with histological differentiation and clinical stage (26). Our finding indicated that SKP1 may play vital roles in the development of HSPCC, which indicates that it may serve as a diagnostic and prognostic biomarker for HSPCC. Apart from SKP1, ZACN (also termed L2, ZAC) was also a hub protein according to the HSPCC-specific PPI network. ZACN is located at chromosome 17, and it encodes zinc-activated ion channel, which belongs to the cysteine-loop superfamily of ligand-gated ion channels. ZACN mRNA is expressed in various organs and tissues, including the brain, pancreas, liver, lung, heart, kidney and skeletal muscle (27). The overexpression of ZACN was implicated in transient neonatal diabetes mellitus, which is a rare inherited diabetic syndrome apparent in neonate and again during early adulthood. In a transgenic mouse model, the expression of human ZACN and hydatidiform mole associated and imprinted (HYMAI) impaired the development of the endocrine pancreas and the function of β cells (28). In the present study, ZACN was the most significantly upregulated gene in the HPSCC dataset compared to the adjacent normal control. The overexpression of ZACN in HPSCC was first reported in this study. The biological roles of ZACN overexpression in HPSCC warrant further investigation in in vitro and in vivo studies. NONO encodes an RNA-binding protein and functions to regulate transcription and RNA splicing in the nucleus. NONO has been implicated in the progression of various tumor types, including breast and colorectal cancer and melanoma. NONO was also reported to regulate lipid metabolism by binding to SREBP-1A in breast cancer (29). Gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA (GAPLINC) promotes cell invasion by targeting snail family transcriptional repressor 2 (SNAI2) via binding with NONO in colorectal cancer (30). As a hub protein of the HSPCC-specific PPI network, NONO was significantly downregulated in HPSCC in this study. In addition, NONO was targeted by hsa-miR-29b-2-5p (Table VI). It has been reported that miR-29b-2-5p was potentially associated with survival in high-grade serous ovarian carcinoma (31). Furthermore, miR-29b-2-5p has been shown to be downregulated in gallbladder cancer (32). It was suggested that NONO may be involved in HPSCC under the regulation of hsa-miR-29b-2-5p. CGB3 is a member of the glycoprotein hormone β chain family and encodes the β 3 subunit of chorionic gonadotropin (33). Previous studies have indicated that the overexpression of CGB3 plays a role in carcinogenesis (34,35). The synthesis of human chorionic gonadotropin β subunit has been detected in 30–50% of various malignant tumors (36,37). In addition, upregulated CGB3 has been found to be closely associated with the metastatic cancer phenotype, resistance to therapy, as well as with a poor prognosis (37,38). To date, to the best of our knowledge, no study has reported the association between CGB3 and HSPCC. In the present study, an increased CGB3 expression was detected in patients with HSPCC. Hence, it can be concluded that CGB3 may be involved in the pathogenesis of HSPCC; however, its precise function warrants further investigation. MALAT1 was the first long non-coding RNA prognostic biomarker identified for early-stage NSCLC (39). The deregulation of MALAT1 has been found in various types of cancer, including lung, breast, pancreas, colon, prostate and liver cancer (40). Previous studies have demonstrated that MALAT1 plays a role in cell proliferation, invasion and tumorigenesis (41–43). In addition, the prognostic value of MALAT1 for cancer metastasis of cancer has been reported (44). The expression of MALAT1 was significantly downregulated in HSPCC in this study, which suggested that MALAT1 may be a key regulator of tumorigenesis in HSPCC. In addition, long-term studies are required in order to identify whether MALAT1 is a predictor for metastasis of HSPCC. CSDE1 (also known as UNR) encodes the RNA-binding protein, which is found to be upregulated in melanoma tumors, and promotes invasion and metastasis (45). The upregulation of CSDE1 has also been identified in breast cancer (46), which suggests that CSDE1 may be involved in tumorigenesis. In the present study, the expression of CSDE1 was downregulated in HSPCC, which may be due to the difference in the type of cancer tissues used. Additionally, this study demonstrated that CSDE1 is under the regulation of hsa-miR-497-5p and hsa-miR-125b-5p (Table VI). The expression of hsa-miR-497-5p has been reported to be significantly decreased in triple-negative breast cancer (47) and to be negatively associated with survival in oropharyngeal squamous cell carcinoma (48). hsa-miR-125b-5p is involved in regulating the proliferation, migration and invasion of tumor cells. The overexpression of hsa-miR-125b-5p has been shown to inhibit cell proliferation, migration and invasion in esophageal squamous cell carcinoma (49). The underlying molecular mechanism of CSDE1 under the regulation of hsa-miR-497-5p and hsa-miR-125b-5p in HPSCC need to be elaborated in future studies. In differentially expressed miRNAs, we observed that hsa-let-7i-5p, hsa-miR-136-5p and hsa-miR-143-5p were the top 3 upregulated miRNAs in HPSCC. hsa-miR-15a-5p, hsa-miR-2278 and hsa-miR-125a-5p were the top 3 downregulated miRNAs in HPSCC. hsa-let-7i-5p has been shown to be upregulated in triple-negative breast cancer cells, colon cancer cells and non-muscle invasive bladder cancer cells (50–52). The upregulation of hsa-let-7i-5p is associated with an advanced stage, a high grade and therefore, with the progression of clear cell renal cell carcinoma (53). hsa-miR-136-5p has been shown to be significantly upregulated in osteosarcoma and colorectal adenocarcinoma (54,55). hsa-miR-143-5p acts as a strong tumor suppressive factor. It has been confirmed that hsa-miR-143-5p inhibits the proliferation, invasion and migration of cervical cancer cells (56). It has also been shown that hsa-miR-15a-5p acted as a tumor suppressor by silencing the expression of growth promoting oncogenes (57–59). In chronic myeloid leukemia, hsa-miR-15a-5p has been shown to suppress cell growth and metastasis (60). In addition, hsa-miR-15a-5p has been shown to be associated with patient survival in lung adenocarcinoma (61). hsa-miR-2278 has been shown to be associated with survival in both rectal and colon cancer (62). hsa-miR-125a-5p is known to act as a tumor suppressor and is downregulated in various malignant tumors, such as laryngeal carcinoma and verrucous carcinoma of the head and neck (63,64). In multiple myeloma cells, the inhibition of hsa-miR-125a-5p has been shown to reduce cell growth, increased cell apoptosis and attenuated cell migration (65). On the whole, these differentially expressed miRNAs may play an important role in the development of HPSCC. In the present study, spliceosome, cell cycle and RNA degradation were significantly enriched signal pathways in HPSCC. Deregulated genes regulated the progression and development of cancer via the cell cycle in various cancer types, including lung adenocarcinoma, colorectal and head and neck cancer (44–46), which indicated that the cell cycle pathway was implicated in the tumorigenesis of HPSCC. In conclusion, in the present study, we identified 160 DEGs and 79 differentially expressed miRNAs in HPSCC tissues compared to adjacent normal tissues. The top 20 upregulated and downregulated genes in HPSCC were used to construct PPI networks, where SKP1, NONO and ZACN were the hub proteins. DEGs were significantly enriched in the spliceosome, cell cycle and RNA degradation. The present study was the first to investigate the gene and mRNA expression profiles in HPSCC. Our findings may provide the groundwork for the identification of early diagnosis biomarkers for HPSCC and the mechanisms that underlie its pathogenesis, as well as make a contribution for future drug design. However, there are limitations to this study. Firstly, the sample size in the RNA-sequencing was small. Therefore, large numbers of HPSCC tumor samples are needed for further research. Secondly, although deregulated genes, miRNAs and pathways in HPSCC were identified, the biological functions of these genes, miRNAs and pathways were not investigated in this study. In vitro and in vivo experiments are essential for the elucidation of the biological roles of DEGs and differentially expressed miRNAs in HPSCC in future investigations. Acknowledgements Not applicable. Funding No funding was received. Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Authors' contributions FW, YF and YL collected the data. FL, WL and XX analyzed and interpreted the data. HL and PG were major contributors in writing the manuscript. HL organized all the data and finally revised the manuscript. PG designed the project. All authors have read and approved the final manuscript. Ethics approval and consent to participate The present study was approved by the Ethics Committee of the First People's Hospital of Jining, and informed written consent was obtained from all patients. Primary tumors and adjacent normal tissues of HPSCC patients were obtained based on the Declaration of Helsinki. Patient consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Abbreviations ADAM10ADAM metallopeptidase CGB3chorionic gonadotropin beta subunit 3 CSDE1cold shock domain containing E1 DEGsdifferentially expressed genes FDRfalse discovery rate FPKMfragments per kilobase of exon per million fragments mapped GRK6G protein-coupled receptor kinase 6 GAPLINCgastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA GOGene Ontology GRP78glucose-regulated protein 78 HYMAIhydatidiform mole associated and imprinted HPSCChypopharyngeal squamous cell carcinoma MALAT1metastasis associated lung adenocarcinoma transcript 1 NONOnon-POU domain containing octamer binding NSCLCnon-small cell lung cancers PPIprotein-protein interaction RPL26ribosomal protein L26 RPS6ribosomal protein S6 RINRNA integrity number SNAI2snail family transcriptional repressor 2 SKP1S-phase kinase associated protein 1 TCGAThe Cancer Genome Atlas TNFR1tumor necrosis factor receptor 1 ZACNzinc activated ion channel ZNF385Czinc finger protein 385C Figure 1. Hierarchical clustering analysis based on the expression profile of the top 20 DEGs in HPSCC compared to adjacent normal tissues. Turquoise and pink indicate the HPSCC and adjacent normal tissues, respectively. Red represents the relative expression level of genes that was higher than the mean expression level, and green represents the relative expression of genes that was lower than the mean expression level. DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma. Figure 2. miRNA target network between DEGs and differentially expressed miRNAs in HPSCC. Diamond and ellipse shapes represent the miRNAs and target genes, respectively. Red and blue represent upregulation and downregulation, respectively. DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma; miRNA, microRNA. Figure 3. Top 15 significantly enriched molecular functions of DEGs in HPSCC. DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma. Figure 4. Top 15 significantly enriched cellular components of DEGs in HPSCC. DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma. Figure 5. Top 15 significantly enriched biological processes of DEGs in HPSCC. DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma. Figure 6. Significantly enriched KEGG pathways of DEGs in HPSCC. DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes. Figure 7. Protein-protein interaction networks of the top 20 upregulated and downregulated DEGs in HPSCC. Red and green rectangle nodes represent upregulated and downregulated DEGs, respectively. Blue circular nodes represent proteins that interact with the proteins encoded by DEG. The solid line indicates the interactions between proteins. Figure 8. Tumor risk evaluations of SKP1, ZACN, NONO, CSDE1, CGB3 and MALAT1 in the TCGA dataset. CGB3, chorionic gonadotropin beta subunit 3; CSDE1, cold shock domain containing E1; MALAT1, metastasis associated in lung adenocarcinoma transcript 1; NONO, non-POU domain containing octamer binding; SKP1, S-phase kinase associated protein 1; TCGA, The Cancer Genome Atlas; ZACN, zinc activated ion channel. Figure 9. Box plots of SKP1, NONO and MALAT1 in the TCGA dataset. MALAT1, metastasis associated in lung adenocarcinoma transcript 1; NONO, non-POU domain containing octamer binding; SKP1, S-phase kinase associated protein 1; TCGA, The Cancer Genome Atlas. Table I. Basic characteristics of patients with HPSCC. Patient ID Age (years) Sex Cigarettes per day Years of smoking Alcohol consumption each day (g) Years of alcohol consumption TNM stage Histological feature Tumor grade 1 62 Male 20 40 100 30 T2N1M0 SCC Medium 2 56 Male 20 30 250 30 T2N1M0 SCC Medium 3 64 Male 20 30 No details No details T3N1M0 SCC Medium HPSCC, hypopharyngeal squamous cell carcinoma. Table II. RNA quantity and quality measurements of 6 samples. Sample ID RNA volume (µl) RNA concentration (ng/µl) RNA amount (µg) RIN 1C 38 2,723 103.47 4 2C 65 2,692 174.98 7.6 3C 27 3,288 88.78 7.5 1N 14 334 4.68 5.7 2N 12 70 0.84 N/A 3N 38 1,784 67.79 4.7 C, primary tissues of hypopharyngeal squamous cell carcinoma; N, adjacent normal tissues; RIN, RNA integrity number; N/A, not available. Table III. RNA-sequencing of the specimens. Sample_ID Total reads Total bases Q20% Q30% Average coverage 1C 4.4×107 5.6×109 96.66 93.47 99.1863479139598 2C 3.5×107 4.3×109 96.61 93.33 99.4073847620807 3C 3.4×107 4.2×109 96.68 93.41 99.2552832336352 1N 4.3×107 5.4×109 96.27 92.79 99.348671268904 3N 3.5×107 4.4×109 96.58 93.32 99.2810150213976 C, primary tissues of hypopharyngeal squamous cell carcinoma; N, adjacent normal tissues; Q20, the percentage of bases with quality value >20; Q30, the percentage of bases with quality value >30. Table IV. DEGs in HPSCC. Gene ID Gene symbol Log2FC P-value FDR Upregulated genes   353174 ZACN 6.288149 8.86E-05 0.038292       1082 CGB3 5.765826 4.12E-05 0.034011   201181 ZNF385C 5.310858 0.000127 0.039757   126567 C2CD4C 5.256596 0.000222 0.049962   84696 ABHD1 5.10952 4.07E-05 0.034011   6370 CCL25 5.035685 5.76E-05 0.035804   693222 MIR637 4.830281 6.51E-05 0.035863   692091 SNORD23 4.628719 3.74E-05 0.033502   9075 CLDN2 4.580931 0.000195 0.047531   6082 SNORD20 4.49704 8.54E-05 0.038072   284339 TMEM145 4.395233 8.36E-05 0.038072   2251 FGF6 3.962287 6.55E-05 0.035863   136371 ASB10 3.961177 0.000138 0.040535   248 ALPI 3.959662 7.79E-05 0.038041   54964 C1orf56 3.849454 0.000166 0.044327   84939 MUM1 3.145926 9.19E-05 0.038292 Downregulated genes   6154 RPL26 −10.6837 1.06E-06 0.014705   6194 RPS6 −9.89489 1.14E-06 0.014705   6500 SKP1 −7.78013 3.26E-06 0.030707   8531 YBX3 −7.37473 2.26E-05 0.033502   347 APOD −7.36529 6.56E-06 0.033502   51614 ERGIC3 −7.28305 0.000122 0.03936   4501 MT1X −6.78769 0.000215 0.049189   3486 IGFBP3 −6.56019 6.70E-06 0.033502   7812 CSDE1 −6.49789 5.73E-06 0.033502   4841 NONO −6.45686 8.40E-06 0.033502   6317 SERPINB3 −6.45555 0.000213 0.049086   5360 PLTP −6.29414 2.00E-05 0.033502   1528 CYB5A −6.28125 2.21E-05 0.033502   51596 CUTA −6.24975 0.000199 0.048247   57035 RSRP1 −6.20271 0.000205 0.048326   7385 UQCRC2 −6.01731 8.71E-06 0.033502   1639 DCTN1 −5.79807 0.000143 0.040725   1212 CLTB −5.70891 0.000204 0.048326   5589 PRKCSH −5.58244 8.30E-05 0.038072   6194 RPS6 −9.89489 1.14E-06 0.014705   340277 FAM221A −3.26588 1.30635 −17.5303 DEGs, differentially expressed genes; HPSCC, hypopharyngeal squamous cell carcinoma; FDR, false discovery rate. Table V. Top 20 differentially expressed miRNAs in HPSCC. miRNA symbol Log2FC P-value Upregulated miRNAs   hsa-let-7i-5p 2.122547495 0   hsa-miR-136-5p 2.444466751 0   hsa-miR-143-5p 2.976688335 0   hsa-miR-370-3p 3.344940583 0   hsa-miR-140-3p 3.395556571 0   hsa-let-7g-5p 9.933859336 8.71E-85   hsa-miR-106b-3p 9.933859336 8.71E-85   hsa-miR-127-3p 9.933859336 8.71E-85   hsa-miR-148b-3p 9.933859336 8.71E-85   hsa-miR-187-3p 9.933859336 8.71E-85 Downregulated miRNAs   hsa-miR-15a-5p −12.79407766 0   hsa-miR-2278 −12.05711064 1.56E-243   hsa-miR-125a-5p −10.472141 3.27E-107   hsa-miR-1269a −10.472141 3.27E-107   hsa-miR-135b-5p −10.472141 3.27E-107   hsa-miR-18a-3p −10.472141 3.27E-107   hsa-miR-19b-3p −10.472141 3.27E-107   hsa-miR-200b-3p −10.472141 3.27E-107   hsa-miR-203b-3p −10.472141 3.27E-107   hsa-miR-20a-5p −10.472141 3.27E-107 HPSCC, hypopharyngeal squamous cell carcinoma. Table VI. Top 10 miRNAs that targeted the majority of genes. miRNA Up/downregulated Count of targets Target genes   hsa-miR-193b-3p Upregulated 18 CDK9, HNRNPUL1, ELK3, ACOT9, GLO1, HPRT1, IRF1, MCM3, NONO, SCLY, RPL26, YBX3, CTSC, ERC1, MDM2, CSDE1,CGNL1, BCAR1   hsa-miR-214-3p Upregulated 17 ERC1, CDK9, SYNPO, NUDT16, DCTN1, CLASP1, ZDHHC8, APOD, INCENP, MYO1E, BIK, TRA2B, TFAM, ITCH, CGNL1, MPZL1, JAG1   hsa-miR-497-5p Upregulated 14 RBBP6, YWHAH, CDS1, CTSC, SYNPO, NUDT16, INCENP, IRF1, CSDE1, PPP1R14C, CGNL1, MPZL1, MTSS1, CDC42SE2   hsa-miR-29b-2-5p Upregulated 13 TMEM18, NUDT16, CPM, CPT1A, ERC1, C2CD3, NFYB, NONO, CXorf40B, LEPROT, TFAM, CGNL1, CTSC   hsa-miR-125b-5p Upregulated 12 EXOC7, LSM4, PIGF, SYNPO, DCTN1, ZDHHC8, IGFBP3, IRF1, NADK, CSDE1, ITCH, MPZL1   hsa-miR-3150b-3p Upregulated 12 KAT7, NUDT16, CPM, ERC1, HCCS, NFYB, CRLS1, LEPROT, PRPSAP2, CDC42SE2, SOD3, TULP3   hsa-miR-185-5p Upregulated 11 KAT7, INCENP, MDM2, NUDT16, CPM, CPT1A, ERC1, HCCS, LEPROT, PPP1R14C, MPZL1   hsa-miR-342-3p Upregulated 11 DARS, ERC1, ACOT9, LETMD1, PRKCSH RPL26, NUDT16, ZDHHC8, CGNL1, MPZL1   hsa-miR-378a-5p Upregulated 11 IRF1, RPS6, CTSC, CPM, CPT1A, ERC1, ANKLE2, FTSJ2, NFYB, TULP3, ITCH   hsa-miR-629-3p Upregulated 11 HNRNPUL1, ACOT9, TRIB1, CDK9, CTSC, NUDT16, CPM, CPT1A, ERC1, SRP54, TFAM ==== Refs References 1 Chaturvedi AK Engels EA Pfeiffer RM Hernandez BY Xiao W Kim E Jiang B Goodman MT Sibug-Saber M Cozen W Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 29 4294 4301 2011 10.1200/jco.2011.29.15_suppl.5529 21969503 2 van Monsjou HS Balm AJ van den Brekel MM Wreesmann VB Oropharyngeal squamous cell carcinoma: A unique disease on the rise? Oral Oncol 46 780 785 2010 10.1016/j.oraloncology.2010.08.011 20920878 3 Hashibe M Brennan P Chuang SC Boccia S Castellsague X Chen C Curado MP Dal Maso L Daudt AW Fabianova E Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium Cancer Epidemiol Biomarkers Prev 18 541 550 2009 10.1158/1055-9965.EPI-08-0347 19190158 4 Chaturvedi AK Engels EA Anderson WF Gillison ML Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States J Clin Oncol 26 612 619 2008 10.1200/JCO.2007.14.1713 18235120 5 Gillison ML Alemany L Snijders PJ Chaturvedi A Steinberg BM Schwartz S Castellsagué X Human papillomavirus and diseases of the upper airway: Head and neck cancer and respiratory papillomatosis Vaccine 30 Suppl 5 F34 F54 2012 10.1016/j.vaccine.2012.05.070 23199965 6 Tartaglia LA Goeddel DV Two TNF receptors Immunol Today 13 151 153 1992 10.1016/0167-5699(92)90116-O 1322675 7 Ashkenazi A Dixit VM Death receptors: Signaling and modulation Science 281 1305 1308 1998 10.1126/science.281.5381.1305 9721089 8 Ma X Li X Lu X Jia L Li H Song Q Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma Tumour Biol 36 9421 9429 2015 10.1007/s13277-015-3684-8 26113409 9 Kaira K Toyoda M Shimizu A Imai H Sakakura K Nikkuni O Suzuki M Iijima M Asao T Chikamatsu K Prognostic significance of GRP78/BiP expression in patients with stage III/IV hypopharyngeal squamous cell carcinoma Neoplasma 63 477 483 2016 10.4149/319_151002N513 26952514 10 Jing P Sa N Liu X Liu X Xu W MicroR-140-5p suppresses tumor cell migration and invasion by targeting ADAM10-mediated Notch1 signaling pathway in hypopharyngeal squamous cell carcinoma Exp Mol Pathol 100 132 138 2016 10.1016/j.yexmp.2015.12.008 26704053 11 Zhou J Li M Yu W Li W Wang J Xiang X Li G Pan X Lei D AB209630, a long non-coding RNA decreased expression in hypopharyngeal squamous cell carcinoma, influences proliferation, invasion, metastasis, and survival Oncotarget 7 14628 14638 2016 26895099 12 Qiu X Chen J Zhang Z You Y Wang Z Aberrant GRK6 promoter methylation is associated with poor prognosis in hypopharyngeal squamous cell carcinoma Oncol Rep 35 1027 1033 2016 10.3892/or.2015.4469 26718636 13 Trapnell C Pachter L Salzberg SL TopHat: Discovering splice junctions with RNA-Seq Bioinformatics 25 1105 1111 2009 10.1093/bioinformatics/btp120 19289445 14 Ghosh S Chan CK Analysis of RNA-Seq data using tophat and cufflinks Methods Mol Biol 1374 339 361 2016 10.1007/978-1-4939-3167-5_18 26519415 15 Ritchie ME Phipson B Wu D Hu Y Law CW Shi W Smyth GK Limma powers differential expression analyses for RNA-sequencing and microarray studies Nucleic Acids Res 43 e47 2015 10.1093/nar/gkv007 25605792 16 Reiner-Benaim A FDR control by the BH procedure for two-sided correlated tests with implications to gene expression data analysis Biom J 49 107 126 2007 10.1002/bimj.200510313 17342953 17 Benjamini Y Hochberg Y Controlling the false discovery rate-a practical and powerful approach to multiple testing J Royal Stat Soc 57 289 300 1995 18 Gołębiowski M Sosnowska A Puzyn T Boguś MI Wieloch W Włóka E Stepnowski P Application of two-way hierarchical cluster analysis for the identification of similarities between the individual lipid fractions of Lucilia sericata Chem Biodivers 11 733 748 2014 10.1002/cbdv.201300294 24827683 19 Smoot ME Ono K Ruscheinski J Wang PL Ideker T Cytoscape 2.8: New features for data integration and network visualization Bioinformatics 27 431 432 2011 10.1093/bioinformatics/btq675 21149340 20 Ochs C Perl Y Halper M Geller J Lomax J Quality assurance of the gene ontology using abstraction networks J Bioinform Comput Biol 14 1642001 2016 10.1142/S0219720016420014 27301779 21 Kanehisa M Sato Y Kawashima M Furumichi M Tanabe M KEGG as a reference resource for gene and protein annotation Nucleic Acids Res 44 D457 D462 2016 10.1093/nar/gkv1070 26476454 22 Chatr-Aryamontri A Breitkreutz BJ Oughtred R Boucher L Heinicke S Chen D Stark C Breitkreutz A Kolas N O'Donnell L The BioGRID interaction database: 2015 update Nucleic Acids Res 43 D470 D478 2015 10.1093/nar/gku1204 25428363 23 Shannon P Markiel A Ozier O Baliga NS Wang JT Ramage D Amin N Schwikowski B Ideker T Cytoscape: A software environment for integrated models of biomolecular interaction networks Genome Res 13 2498 2504 2003 10.1101/gr.1239303 14597658 24 Keaton MA Morgan DO: The cell cycle: Principles of control (Primers in Biology) Cell Division 2 27 2007 10.1186/1747-1028-2-27 25 Liu YQ Wang XL Cheng X Lu YZ Wang GZ Li XC Zhang J Wen ZS Huang ZL Gao QL Skp1 in lung cancer: Clinical significance and therapeutic efficacy of its small molecule inhibitors Oncotarget 6 34953 34967 2015 26474281 26 Xu M Yang X Zhao J Zhang J Zhang S Huang H Liu Y Liu J High expression of Cullin1 indicates poor prognosis for NSCLC patients Pathol Res Pract 210 397 401 2014 10.1016/j.prp.2014.01.015 24767980 27 Houtani T Munemoto Y Kase M Sakuma S Tsutsumi T Sugimoto T Cloning and expression of ligand-gated ion-channel receptor L2 in central nervous system Biochem Biophys Res Commun 335 277 285 2005 10.1016/j.bbrc.2005.07.079 16083862 28 Ma D Shield JP Dean W Leclerc I Knauf C Burcelin R Ré Rutter GA Kelsey G Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM J Clin Invest 114 339 348 2004 10.1172/JCI200419876 15286800 29 Zhu Z Zhao X Zhao L Yang H Liu L Li J Wu J Yang F Huang G Liu J p54nrb /NONO regulates lipid metabolism and breast cancer growth through SREBP-1A Oncogene 35 1399 1410 2016 10.1038/onc.2015.197 26148231 30 Yang P Chen T Xu Z Zhu H Wang J He Z Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO Oncotarget 7 42183 42194 2016 27259250 31 Vilming Elgaaen B Olstad OK Haug KB Brusletto B Sandvik L Staff AC Gautvik KM Davidson B Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker BMC cancer 14 80 2014 10.1186/1471-2407-14-80 24512620 32 Chandra V Kim JJ Mittal B Rai R MicroRNA aberrations: An emerging field for gallbladder cancer management World J Gastroenterol 22 1787 1799 2016 10.3748/wjg.v22.i5.1787 26855538 33 Kubiczak M Walkowiak GP Nowak-Markwitz E Jankowska A Human chorionic gonadotropin beta subunit genes CGB1 and CGB2 are transcriptionally active in ovarian cancer Int J Mol Sci 14 12650 12660 2013 10.3390/ijms140612650 23774837 34 Hotakainen K Lintula S Jarvinen R Paju A Stenman J Rintala E Stenman UH Overexpression of human chorionic gonadotropin beta genes 3, 5 and 8 in tumor tissue and urinary cells of bladder cancer patients Tumour Biol 28 52 56 2007 10.1159/000097703 17139196 35 Hotakainen K Lintula S Ljungberg B Finne P Paju A Stenman UH Stenman J Expression of human chorionic gonadotropin beta-subunit type I genes predicts adverse outcome in renal cell carcinoma J Mol Diagn 8 598 603 2006 10.2353/jmoldx.2006.060076 17065429 36 Iles RK Ectopic hCGbeta expression by epithelial cancer: Malignant behaviour, metastasis and inhibition of tumor cell apoptosis Mol Cell Endocrinol 260-262 264 270 2007 10.1016/j.mce.2006.02.019 17069968 37 Iles RK Delves PJ Butler SA Does hCG or hCGβ play a role in cancer cell biology? Mol Cell Endocrinol 329 62 70 2010 10.1016/j.mce.2010.07.014 20654692 38 Hotakainen K Ljungberg B Haglund C Nordling S Paju A Stenman UH Expression of the free beta-subunit of human chorionic gonadotropin in renal cell carcinoma: Prognostic study on tissue and serum Int J Cancer 104 631 635 2003 10.1002/ijc.11000 12594819 39 Wu Y Lu W Xu J Shi Y Zhang H Xia D Prognostic value of long non-coding RNA MALAT1 in cancer patients Tumour Biol 37 897 903 2016 10.1007/s13277-015-3870-8 26254614 40 Lin R Maeda S Liu C Karin M Edgington TS A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas Oncogene 26 851 858 2007 10.1038/sj.onc.1209846 16878148 41 Yang MH Hu ZY Xu C Xie LY Wang XY Chen SY Li ZG MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9 Biochim Biophys Acta 1852 166 174 2015 10.1016/j.bbadis.2014.11.013 25446987 42 Wu XS Wang XA Wu WG Hu YP Li ML Ding Q Weng H Shu YJ Liu TY Jiang L MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway Cancer Biol Ther 15 806 814 2014 10.4161/cbt.28584 24658096 43 Ying L Chen Q Wang Y Zhou Z Huang Y Qiu F Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition Mol Biosyst 8 2289 2294 2012 10.1039/c2mb25070e 22722759 44 Tano K Akimitsu N Long non-coding RNAs in cancer progression Front Genet 3 219 2012 10.3389/fgene.2012.00219 23109937 45 Wurth L Papasaikas P Olmeda D Bley N Calvo GT Guerrero S Cerezo-Wallis D Martinez-Useros J García-Fernández M Hüttelmaier S UNR/CSDE1 drives a post-transcriptional program to promote melanoma invasion and metastasis Cancer Cell 30 694 707 2016 10.1016/j.ccell.2016.10.004 27908735 46 Fang H Yue X Li X Taylor JS Identification and characterization of high affinity antisense PNAs for the human unr (upstream of N-ras) mRNA which is uniquely overexpressed in MCF-7 breast cancer cells Nucleic Acids Res 33 6700 6711 2005 10.1093/nar/gki968 16314303 47 Chang YY Kuo WH Hung JH Lee CY Lee YH Chang YC Lin WC Shen CY Huang CS Hsieh FJ Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing Mol Cancer 14 36 2015 10.1186/s12943-015-0301-9 25888956 48 Wong N Khwaja SS Baker CM Gay HA Thorstad WL Daly MD Lewis JS Jr Wang X Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas Cancer Med 5 1619 1628 2016 10.1002/cam4.718 27109697 49 Mei LL Wang WJ Qiu YT Xie XF Bai J Shi ZZ miR-125b-5p functions as a tumor suppressor gene partially by regulating HMGA2 in esophageal squamous cell carcinoma PLoS One 12 e0185636 2017 10.1371/journal.pone.0185636 28968424 50 Qattan A Intabli H Alkhayal W Eltabache C Tweigieri T Amer SB Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients BMC Cancer 17 799 2017 10.1186/s12885-017-3776-5 29183284 51 Choo KB Soon YL Nguyen PN Hiew MS Huang CJ MicroRNA-5p and −3p co-expression and cross-targeting in colon cancer cells J Biomed Sci 21 95 2014 10.1186/s12929-014-0095-x 25287248 52 Armstrong DA Green BB Seigne JD Schned AR Marsit CJ MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer Mol Cancer 14 194 2015 10.1186/s12943-015-0466-2 26576778 53 Gowrishankar B Ibragimova I Zhou Y Slifker MJ Devarajan K Al-Saleem T Uzzo RG Cairns P MicroRNA expression signatures of stage, grade, and progression in clear cell RCC Cancer Biol Ther 15 329 341 2014 10.4161/cbt.27314 24351440 54 Lauvrak SU Munthe E Kresse SH Stratford EW Namløs HM Meza-Zepeda LA Myklebost O Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes Br J Cancer 109 2228 2236 2013 10.1038/bjc.2013.549 24064976 55 Zheng G Du L Yang X Zhang X Wang L Yang Y Li J Wang C Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma Br J Cancer 111 1985 1992 2014 10.1038/bjc.2014.489 25233400 56 Jin X Chen X Hu Y Ying F Zou R Lin F Shi Z Zhu X Yan X Li S Zhu H LncRNA-TCONS_00026907 is involved in the progression and prognosis of cervical cancer through inhibiting miR-143-5p Cancer Med 6 1409 1423 2017 10.1002/cam4.1084 28544557 57 Calin GA Cimmino A Fabbri M Ferracin M Wojcik SE Shimizu M Taccioli C Zanesi N Garzon R Aqeilan RI MiR-15a and miR-16-1 cluster functions in human leukemia Proc Natl Acad Sci USA 105 5166 5171 2008 10.1073/pnas.0800121105 18362358 58 Pekarsky Y Croce CM Role of miR-15/16 in CLL Cell Death Differ 22 6 11 2015 10.1038/cdd.2014.87 24971479 59 Huang E Liu R Chu Y miRNA-15a/16: As tumor suppressors and more Future Oncol 11 2351 2363 2015 10.2217/fon.15.101 26260813 60 Chen D Wu D Shao K Ye B Huang J Gao Y MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia Am J Transl Res 9 4308 4316 2017 28979704 61 Yanaihara N Caplen N Bowman E Seike M Kumamoto K Yi M Stephens RM Okamoto A Yokota J Tanaka T Unique microRNA molecular profiles in lung cancer diagnosis and prognosis Cancer Cell 9 189 198 2006 10.1016/j.ccr.2006.01.025 16530703 62 Slattery ML Pellatt AJ Lee FY Herrick JS Samowitz WS Stevens JR Wolff RK Mullany LE Infrequently expressed miRNAs influence survival after diagnosis with colorectal cancer Oncotarget 8 83845 83859 2017 10.18632/oncotarget.19863 29137387 63 Yao XD Li P Wang JS MicroRNA differential expression spectrum and microRNA-125a-5p inhibition of laryngeal cancer cell proliferation Exp Ther Med 14 1699 1705 2017 10.3892/etm.2017.4685 28810638 64 Odar K Boštjančič E Gale N Glavač D Zidar N Differential expression of microRNAs miR-21, miR-31, miR-203, miR-125a-5p and miR-125b and proteins PTEN and p63 in verrucous carcinoma of the head and neck Histopathology 61 257 265 2012 10.1111/j.1365-2559.2012.04242.x 22690848 65 Leotta M Biamonte L Raimondi L Ronchetti D Di Martino MT Botta C Leone E Pitari MR Neri A Giordano A A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells J Cell Physiol 229 2106 2116 2014 10.1002/jcp.24669 24819167